Trials / Completed
CompletedNCT00704288
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 222 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL184 | Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2012-06-01
- Completion
- 2012-12-01
- First posted
- 2008-06-24
- Last updated
- 2024-02-05
- Results posted
- 2024-02-05
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00704288. Inclusion in this directory is not an endorsement.